Interim report January-March 2007
• Net sales increased by 7 percent to SEK 49.2 (46.0) million. Adjusted for
exchange rate effects, the increase was 12 percent.
• Gross income increased by 12 percent to SEK 33.8 (30.1) million, and the gross
margin improved to 69 percent (65).
• Operating income increased by 48 percent and amounted to SEK 8.0 (5.4)
million, which gives an operating margin of 16 percent (12).
• Operating income before research and development costs increased by 28 percent
to SEK 14.6 (11.4) million. This corresponds to a margin of 30 percent (25).
• Continued strong focus on research and development activities, 13.4 percent
(12.9) of sales.
• Consolidated net income was SEK 11.0 (4.3) million. Capitalization of the
deferred tax asset in loss carry-forward for tax purposes has been carried out
to the tune of SEK 4.1 (-) million.
• The cash flow from operating activities amounted to SEK 5.0 (0.5) million.
• Earnings per share amounted to SEK 0.55 (0.22).
• The equity/assets ratio amounted to 82 percent (77).
May 3, 2007
Kungsbacka, Sweden
Magnus Nilsson
CEO
Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.
________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced one-time instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation product
area works with solutions and systems to maintain tissue in optimal condition
outside the body for the required time while waiting for transplantation. The
Stem Cell Cultivation product area works with media and instruments to enable
the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 120 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.
Interim report January-March 2007
| Source: Vitrolife AB
Attachments
